Merck & Co. Inc. has announced promising results from the Phase 1 KANDLELIT-001 study, which evaluated MK-1084, an investigational KRAS G12C inhibitor, in patients with advanced colorectal cancer and non-small cell lung cancer harboring KRAS G12C mutations. The study demonstrated a manageable safety profile and encouraging antitumor activity for MK-1084, both as a monotherapy and in combination with other treatments. In non-small cell lung cancer, MK-1084 in combination with KEYTRUDA showed an objective response rate $(ORR.AU)$ of 77% in untreated metastatic patients with PD-L1 expression, while as a monotherapy, it achieved an ORR of 38% in previously treated patients. The findings suggest significant potential for MK-1084 in addressing prevalent KRAS mutations in cancer, representing a promising advancement in Merck's oncology pipeline.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。